{"nctId":"NCT00735371","briefTitle":"Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)","startDateStruct":{"date":"2008-10-08","type":"ACTUAL"},"conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"count":314,"armGroups":[{"label":"Lisdexamfetamine Dimesylate (LDX) 30 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: LDX 30 mg"]},{"label":"LDX 50 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: LDX 50 mg"]},{"label":"LDX 70 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: LDX 70 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"LDX 30 mg","otherNames":["Vyvanse"]},{"name":"LDX 50 mg","otherNames":[]},{"name":"LDX 70 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meet DSM-IV-TR criteria for a primary diagnosis of ADHD\n* Baseline ADHD-RS-IV score \\>=28\n* BP w/in 95th percentile for age, gender, and height\n\nExclusion Criteria:\n\n* Subject has controlled or uncontrolled comorbid psychiatric diagnosis\n* Subject has conduct disorder\n* Suicidal\n* Under or overweight\n* Concurrent chronic or acute illness that might confound results.","healthyVolunteers":false,"sex":"ALL","minimumAge":"13 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks","description":"The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.3","spread":"1.25"},{"groupId":"OG001","value":"-21.1","spread":"1.28"},{"groupId":"OG002","value":"-20.7","spread":"1.25"},{"groupId":"OG003","value":"-12.8","spread":"1.25"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores","description":"Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Youth Quality of Life-Research Version (YQOL-R) Total Score","description":"The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":"10.03"},{"groupId":"OG001","value":"80.5","spread":"10.63"},{"groupId":"OG002","value":"78.8","spread":"15.38"},{"groupId":"OG003","value":"79.2","spread":"11.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1","spread":"11.09"},{"groupId":"OG001","value":"81.3","spread":"11.86"},{"groupId":"OG002","value":"81.3","spread":"14.66"},{"groupId":"OG003","value":"81.3","spread":"12.16"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":78},"commonTop":["Decreased appetite","Headache","Insomnia","Weight decreased","Irritability"]}}}